Advertisement

Malattia di Parkinson

  • Floriano Girotti
  • Vincenza Fetoni

Riassunto

La malattia di Parkinson (MP) è una patologia neurodegenerativa evolutiva e rappresenta una delle più frequenti malattie neurologiche dell’età media-avanzata. La prevalenza nella popolazione generale è di 120–180 casi per 100.000 individui; l’incidenza e la prevalenza aumentano con il progredire dell’età. È possibile un esordio precoce di malattia nel 5–10% dei pazienti in cui i sintomi iniziali compaiono tra i 21 e 40 anni. In forme più rare, definite a esordio giovanile, i sintomi compaiono prima dei 20 anni.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24:197–211.CrossRefPubMedGoogle Scholar
  2. 2.
    Suchowersky O, Gronseth G, Perlmutter J et al. Practise Parameter: Neuropropective strategies and alternative therapies for Parkinson disease(an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:976–982.CrossRefPubMedGoogle Scholar
  3. 3.
    Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson’s disease. Report of a Joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. European Journal of Neurology 2006;13:1170–1185.CrossRefPubMedGoogle Scholar
  4. 4.
    Myllyla VV, Sotaniemi KA, Vuorinen JA et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42:339–342.PubMedGoogle Scholar
  5. 5.
    Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39:37–41.CrossRefGoogle Scholar
  6. 6.
    Parkinson Study Group. A controlled trial of rasagiline in early Parkinsons disease. The Tempo study. Arch Neurol 2004; 59:1937–1943.CrossRefGoogle Scholar
  7. 7.
    Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61:561–566.CrossRefGoogle Scholar
  8. 8.
    Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. NEJM 2004; 351:2498–2508.CrossRefGoogle Scholar
  9. 9.
    Olanow CW, Hauser RA, Gauger L et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995; 38:771–777.CrossRefPubMedGoogle Scholar
  10. 10.
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexolo vs levodopa on Parkinson disease progression. J Am Med Ass 2002; 287:1653–1661.CrossRefGoogle Scholar
  11. 11.
    Whone AL, Watts RL, Stoess AJ et al. Slower progression of Parkinson’s disease with ropinerolo versus levodopa: the Real-Pet study. Ann Neurol 2003; 54:93–101.CrossRefPubMedGoogle Scholar
  12. 12.
    Goetz Cg, Koller WC, Poewe W et al. Management of Parkinson’s disease: a evidence-based rewiew. Mov Disord 2002; 17:S1–S166.CrossRefGoogle Scholar
  13. 13.
    Nyholm D. The rationale for continuos dopaminergic stimulation in advanced Parkinson’s Disease. Parkinsonism and Related Disorders 2007; 13:S13–S17.CrossRefPubMedGoogle Scholar
  14. 14.
    Calon F, Hadj TA, Blanchet PJ et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 2000; 23 (supll 10): S92–100.CrossRefPubMedGoogle Scholar
  15. 15.
    Shannon Km, Bennet JP, Friedman JH. Efficacy of pramipexolo, a noveel dopaminoagoniste, as mono-therapy in mild tomoderate Parkinson’s disease. The Pramipexolo Study Group. Neurology 1997; 49:724–728.PubMedGoogle Scholar
  16. 16.
    Adler Ch, Sethi KD, Hauser RA et al. Ropinirolo for the treatment of early Parkinson’s disease. Neurology 1997; 49:393–399.PubMedGoogle Scholar
  17. 17.
    Rascol O, Brooks DJ et al. A five year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirolo or levodopa. New Engl J Med 2000; 342:1484–1491.CrossRefPubMedGoogle Scholar
  18. 18.
    Zadikoff C, Rochon P, Lang A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006; 33:27–33.PubMedGoogle Scholar
  19. 19.
    Dhawn U, Medcalf P, Stegie F et al. Retrospective evaluation of cardio-polmonary fibrotic side effects in symtptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neurol Trasm 2005; 112:661–668.CrossRefGoogle Scholar
  20. 20.
    Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurology 2007; 6:826–829.CrossRefPubMedGoogle Scholar
  21. 21.
    Pahwa R, Stacy MA, Factor DO et al: Ropinirolo 24-hour prolonged release. Randomized, controlled study in advanced Parkinsons disease. Neurology 2007; 68:1108–1115.CrossRefPubMedGoogle Scholar
  22. 22.
    Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68:272–276.CrossRefPubMedGoogle Scholar
  23. 23.
    LeWitt PA, Lyons KE, Pahwa R et al: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68:1262–1267.CrossRefPubMedGoogle Scholar
  24. 24.
    Stacy M, Silver D. Apomorfine for the acute treatment of “off” episodes in Parkinson’s Disease. Parkinsonism and Related Disorders 2008; 14:85–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Bonifati V, Meco G. New selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson’s disease. Pharmacology and Therapeutics 1999; 81(1):1–36.CrossRefPubMedGoogle Scholar
  26. 26.
    The Entacapone to Tolcapone Switch Study Investigators. Entacapone to Tolcapone switch multicenter double-blind, randomised, active-controlled trial in advanced Parkinson’s disease. Mov Disord 2007; 22(1):14–19.CrossRefGoogle Scholar
  27. 27.
    Myllyla Vhaapaniemi TA et al. New triple combination levodopa/carbidopa/entacapone is a preferred treatment in patients with Parkinson’s disease. Neurology 2003, 60 (suppl.).Google Scholar
  28. 28.
    Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol 2005; 62:241–248.CrossRefGoogle Scholar
  29. 29.
    Bonuccelli U, Ceravolo R, Solvetti S et al. Clozapine in Parkinson’s disease tremor. Effect of acute and chronicadministration. Neurology 1997; 49:1587–1590.PubMedGoogle Scholar
  30. 30.
    Crosby NJ, Deane KHO, Clarke CE. Beta-blocker therapy for tremor in Parkinson’s disease. Cochrane Database Systemic Reviews 2003;1:CD003361.Google Scholar
  31. 31.
    Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson’s disease. Report of a Joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part II: late (complicated) Parkinson’s disease. Eur J Neurol 2006; 13:1170–1185.CrossRefPubMedGoogle Scholar
  32. 32.
    Pahwa R, Factor DO et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology 2006; 66:983–995.CrossRefPubMedGoogle Scholar
  33. 33.
    Durif F, Debilly B, Galitzky M. Clozapine improves dyskinesias in Parkinsons disease: a double-blind placebo-controlled study. Neurology 2004; 62:381–388.PubMedGoogle Scholar
  34. 34.
    Katznschlager R, Manson AJ, Evans A et al. Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease-a double blind cross over study. J Neurol Neurosurg Psychiatry 2004; 75:295–297.Google Scholar
  35. 35.
    Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149:443–454.PubMedGoogle Scholar
  36. 36.
    Rektorovà, Rektor I, Bares M et al. Pramipexole sand pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399–406.CrossRefPubMedGoogle Scholar
  37. 37.
    Ghazi-Noori S, Chung TH, Deane KHO et al. Therapies for depression in Parkinson’s disease. Cochrane Database of Systemic Reviews 2003; 2:CD3465.Google Scholar
  38. 38.
    Ceravolo R, Nuti A, Piccinni A et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000; 55:1216–1218.PubMedGoogle Scholar
  39. 39.
    Ravina B, Marden K, Fernandez HH et al. Diagnostic Criteria for Psychosis in Parkinson’s Disease: Report of NINDS, NIMH Work Group. Mov Disord 2007; 22,8: 1061–1068.CrossRefGoogle Scholar
  40. 40.
    Graham JM, Grunewald RA et al Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psichiatry 1997; 63:434–440.CrossRefGoogle Scholar
  41. 41.
    Reaching P, Luca A, McKeith I. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment. Mov Disord 2001; 16:1171–1174.CrossRefGoogle Scholar
  42. 42.
    Fabbrini G, Barbanti P, Aurilia C et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23:41–43.CrossRefPubMedGoogle Scholar
  43. 43.
    Weintraub D, Siderowf AD, Potenza MN et al. Asociation of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63:969–973.CrossRefPubMedGoogle Scholar
  44. 44.
    Schrag A. Psychiatric aspects of Parkinson’s diseasean update. J Neurol 2004; 251:795–804.CrossRefPubMedGoogle Scholar
  45. 45.
    Senard JM, Rai S, Lapeyere-Mestre et al. Prevalence of orthostatic in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 584–589.CrossRefPubMedGoogle Scholar
  46. 46.
    Low PA, Gilden FL, Freeman R et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized double-blind multicenter study.Midodrine study group. JAMA 1997; 277:1046–1051.CrossRefPubMedGoogle Scholar
  47. 47.
    Hoehn MM. L-Dopa induced postural hypotension. Treatment with fludrocortisone. Arch Neurol 1975; 32:50–51.PubMedGoogle Scholar
  48. 48.
    Schoffer KL, Henderson RD, O’Maley K et al. Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord 2007; 22,11:1543–1549.CrossRefPubMedGoogle Scholar
  49. 49.
    Cordivari C, Misra VP, Catania S et al. New therapeutic indications for botulinum toxins. Mov Dis 2004,19, Suppl. 18: S157–S151.CrossRefGoogle Scholar
  50. 50.
    Lozano AM, Lang AE. Pallidotomy for Parkinson’s disease. Adv Neurol 2001; 83:413–420.Google Scholar
  51. 51.
    Rodriguez-Oroz MC et al Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 2005; 128:2240–2249.CrossRefPubMedGoogle Scholar
  52. 52.
    Liang GS, Chou KL et al. Long-term outcomes of bilateral sbthalamic nucleus stimulation in patients with advanced Parkinson’s disease. Stereotact Funct Neurosurg 2006; 84:221–227.CrossRefPubMedGoogle Scholar
  53. 53.
    Videnovic A, Metman LE. Deep Brain Stimulation for Parkinson’s Disease: Prevalence of Adverse Events and Need for Standardized Reporting. Mov Disord 2008; 23, 3:343–349.CrossRefPubMedGoogle Scholar
  54. 54.
    Volkmann J, Allert N, Voges J et al. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Ann Neurol 2004; 55:871–875.CrossRefPubMedGoogle Scholar
  55. 55.
    Freed CR, Breeze RE, Rosenberg NL et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Eng J Med 1992; 327:1549–1555.Google Scholar
  56. 56.
    Kordower JH, Freeman TB, Snow BJ et al. Neuropathological evidence of graft survival and striatal reinnervation after transplantation of fetal mesencephalic tissue in a patients with Parkinson’s disease. N Eng J Med 1995; 332:1118–1124.CrossRefGoogle Scholar
  57. 57.
    Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Eng J Med 2001; 344:710–719.CrossRefGoogle Scholar
  58. 58.
    Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003; 54:403–414.CrossRefPubMedGoogle Scholar
  59. 59.
    Slevin JT, Gash DM, Smith CD et al. Unilateral intraputaminal glia cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 yera of treatment and 1 yera of withdrawal.J Neurosurg 2007; 106(4):614–620.CrossRefPubMedGoogle Scholar
  60. 60.
    Kaplitt MG, Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial.Lancet 2007; 369:2097–2105.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Floriano Girotti
    • 1
  • Vincenza Fetoni
    • 2
  1. 1.Unità Operativa di Neurologia Dipartimento di Neuroscienze ClinicheFondazione Istituto Neurologico “C. Besta”Milano
  2. 2.Unità Operativa di NeurologiaAzienda Ospedaliera di MelegnanoMelegnano (MI)

Personalised recommendations